← Back to Clinical Trials
Recruiting Phase 4 NCT05674630

NCT05674630 Ticin for the Treatment of Coronary Lesions With Drug Eluting Ballons

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05674630
Status Recruiting
Phase Phase 4
Sponsor Cardiocentro Ticino
Condition Chronic Coronary Syndrome
Study Type INTERVENTIONAL
Enrollment 130 participants
Start Date 2023-02-21
Primary Completion 2026-06-01

Trial Parameters

Condition Chronic Coronary Syndrome
Sponsor Cardiocentro Ticino
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 130
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-02-21
Completion 2026-06-01
Interventions
Magic Touch drug eluting balloon based strategyDrug-eluting stent-based strategy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to compare the use of a specific drug eluting balloon (Magic Touch, Concept Medical®) versus standard drug eluting stent based strategies in patients with long coronary lesions. Participants with chronic coronary disease and long coronary stenosis will be randomly assign to be treated either with Magic Touch balloon or drug eluting stent.

Eligibility Criteria

Inclusion Criteria: 1. Adult patients (≥18 years old) with chronic coronary syndrome deemed suitable for PCI 2. At least one significant de-novo coronary lesion (defined as diameter stenosis \> 50% on angiography, with flow limiting features, confirmed with FFR ≤0.80 or iFR ≤0.89 and intended implantation of a long (≥30 mm) DES based on IVUS findings 3. Written informed consent Exclusion Criteria: 1. Patients referred to the index procedure for an acute coronary syndrome 2. Target lesion involving the left main and/or ostial left coronary artery, ostial left circumflex artery or ostial right coronary artery 3. Severe renal impairment (eGFR\<15ml/min/1.73m2) or patient on dialysis treatment 4. Spontaneous coronary artery dissection (SCAD) 5. Contraindications to adenosine administration (e.g. moderate to severe asthma or chronic obstructive pulmonary disease, heart rate \<50 beats/min and systolic blood pressure \<90 mmHg) 6. Known pregnancy or breast-feeding patients 7. Life expectancy

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology